{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:00Z","timestamp":1792788480940,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Youth Project of Natural Science Foundation of Henan Province","award":["222300420225"],"award-info":[{"award-number":["222300420225"]}]},{"name":"Special Research Project of Traditional Chinese Medicine in Henan Province","award":["20-21ZY2006"],"award-info":[{"award-number":["20-21ZY2006"]}]},{"name":"Henan Provincial Health Commission, National Clinical Research Base of Traditional Chinese Medicine","award":["2019JDZX2020"],"award-info":[{"award-number":["2019JDZX2020"]}]},{"name":"Post-doctoral Research Project of Henan Province","award":["HN2024106"],"award-info":[{"award-number":["HN2024106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Qingying decoction (QYD) is a traditional prescription in China that has been shown to be effective in treating psoriasis. However, its mechanism of action remains to be elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The active ingredients and targets of QYD were obtained from TCMSP database, HERB database and SwissTargetPrediction database, respectively. Differential expression gene (DEGs) analysis and weighted gene co-expression network analysis (WGCNA) were used to identify key genes associated with psoriasis. Protein-protein interaction (PPI) network was constructed using STRING platform. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed using the DAVID database and the clusterProfiler package of R software. Cytoscape 3.9.0 software was used to screen the key components of QYD and the hub targets. Molecular docking was used to detect the binding ability between key components and hub targets. An in vitro model of psoriasis was established by stimulating keratinocyte HaCaT with a mixture of five pro-inflammatory cytokines (IL-17\u00a0A, IL-22, IL-1\u03b1, oncostatin M, and TNF-\u03b1) (M5). Cell viability and cell cycle were measured using cell counting Kit 8 (CCK-8) and flow cytometry, respectively. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect mRNA levels of hub genes, high-proliferation marker keratin 6 (KRT6) and inflammatory factors IL-1\u03b2, IL-6 and TNF-\u03b1. Protein expression levels of PI3K\/AKT\/FoxO pathway related targets were detected by Western blot.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 139 active ingredients of QYD were screened in this study, with 1033 targets, 59 of which overlapped with psoriasis-related genes. Quercetin, luteolin, kaempferol, beta-sitosterol and methylophiopogonanone A were considered to be the key ingredients of QYD in the treatment of psoriasis. CDC25A, TOP2A, NEK2 and CCNA2 were identified to be the hub targets. QYD could probably regulate cell cycle, T cell receptor signaling pathway and metabolic pathway to treat psoriasis. The key components of QYD had good binding affinity with hub target proteins. QYD significantly attenuated M5-induced hyperproliferation and cell cycle progression of HaCaT cells. M5 stimulation significantly upregulates the mRNA levels of CDC25A, TOP2A, NEK2, CCNA2, IL-1\u03b2, IL-6 and TNF-\u03b1, while QYD treatment reversed this effect. In addition, QYD treatment inhibited the phosphorylation of PI3K and AKT in M5-stimulated HaCaT cells and upregulated p-FOXO1 protein expression level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>QYD can inhibit the excessive proliferation and inflammatory response of keratinocytes by regulating the PI3K\/AKT\/FoxO pathway, suggesting that QYD may be an attractive prescription for psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-025-00421-8","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:48:43Z","timestamp":1743983323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Application of bioinformatics analysis and molecular docking to study the mechanism of Qingying decoction in treating psoriasis"],"prefix":"10.1186","volume":"162","author":[{"given":"Cuicui","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangchao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"6","key":"421_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"key":"421_CR2","doi-asserted-by":"publisher","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, Guo C, Dellavalle R, Grada A, Wong P, La Vecchia C, Tam LS, Cooper KD, Naghavi M. The global, regional, and National burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8:743180.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"421_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/jcm10051031","volume":"10","author":"A Ruggiero","year":"2021","unstructured":"Ruggiero A, Fabbrocini G, Cacciapuoti S, Cinelli E, Gallo L, Megna M. Ocular manifestations in psoriasis screening (OcMaPS) questionnaire: A useful tool to reveal misdiagnosed ocular involvement in psoriasis. J Clin Med. 2021;10(5):1031.","journal-title":"J Clin Med"},{"issue":"4","key":"421_CR4","first-page":"279","volume":"158","author":"E Carmona-Rocha","year":"2023","unstructured":"Carmona-Rocha E, Puig L. The biological basis of disease recurrence in psoriasis. Ital J Dermatol Venerol. 2023;158(4):279\u201391.","journal-title":"Ital J Dermatol Venerol"},{"issue":"10281","key":"421_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis Lancet. 2021;397(10281):1301\u201315.","journal-title":"Psoriasis Lancet"},{"issue":"17","key":"421_CR6","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/ijms241713313","volume":"24","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 2023;24(17):13313.","journal-title":"Int J Mol Sci"},{"key":"421_CR7","first-page":"3193572","volume":"2022","author":"X Yang","year":"2022","unstructured":"Yang X, Luo G, Fu L, Huang H, Wang L, Yin L, Zhang X, Wang T, Ma X, Feng T, Ye J. Intervention mechanism of Hunag-Lian Jie-Du Decoction on canonical Wnt\/\u03b2-Catenin signaling pathway in psoriasis mouse model. Evid Based Complement Alternat Med. 2022;2022:3193572.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"6","key":"421_CR8","first-page":"96","volume":"28","author":"Z Tian","year":"2022","unstructured":"Tian Z, Cang R, Lei M, et al. Enhanced effect of Qing-Ying Decoction concurrent with Secukinumab in the treatment of plaque psoriasis. Altern Ther Health Med. 2022;28(6):96\u2013102.","journal-title":"Altern Ther Health Med"},{"issue":"3","key":"421_CR9","first-page":"290","volume":"35","author":"DC Fu","year":"2015","unstructured":"Fu DC, Hua Z, Li YG, Wu HY, Guo XY, Huang JZ. [Treatment of early and mid-term primary biliary cirrhosis by Qingying Huoxue Decoction combined ursodeoxycholic acid: a clinical observation]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(3):290\u20133. Chinese. PMID: 25951632.","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"issue":"11","key":"421_CR10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682\u201390.","journal-title":"Nat Chem Biol"},{"issue":"23","key":"421_CR11","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1111\/jcmm.17967","volume":"27","author":"Z Liu","year":"2023","unstructured":"Liu Z, Huang H, Yu Y, Li L, Shi X, Wang F. Exploring the mechanism of ellagic acid against gastric cancer based on bioinformatics analysis and network Pharmacology. J Cell Mol Med. 2023;27(23):3878\u201396.","journal-title":"J Cell Mol Med"},{"key":"421_CR12","doi-asserted-by":"publisher","first-page":"Article17","DOI":"10.2202\/1544-6115.1128","volume":"4","author":"B Zhang","year":"2005","unstructured":"Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article17.","journal-title":"Stat Appl Genet Mol Biol"},{"key":"421_CR13","doi-asserted-by":"publisher","first-page":"104894","DOI":"10.1016\/j.compbiomed.2021.104894","volume":"138","author":"Y Zeng","year":"2021","unstructured":"Zeng Y, Xiao S, Yang L, Ma K, Shang H, Gao Y, Wang Y, Zhai F, Xiang R. Systematic analysis of the mechanism of Xiaochaihu Decoction in hepatitis B treatment via network Pharmacology and molecular Docking. Comput Biol Med. 2021;138:104894.","journal-title":"Comput Biol Med"},{"issue":"1","key":"421_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13020-021-00534-y","volume":"16","author":"C Wu","year":"2021","unstructured":"Wu C, Huang ZH, Meng ZQ, Fan XT, Lu S, Tan YY, You LM, Huang JQ, Stalin A, Ye PZ, Wu ZS, Zhang JY, Liu XK, Zhou W, Zhang XM, Wu JR. A network Pharmacology approach to reveal the Pharmacological targets and biological mechanism of compound Kushen injection for treating pancreatic cancer based on WGCNA and in vitro experiment validation. Chin Med. 2021;16(1):121.","journal-title":"Chin Med"},{"issue":"1","key":"421_CR15","doi-asserted-by":"publisher","first-page":"10258","DOI":"10.1038\/s41598-020-66986-8","volume":"10","author":"M Yi","year":"2020","unstructured":"Yi M, Nissley DV, McCormick F, Stephens RM. SsGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications. Sci Rep. 2020;10(1):10258.","journal-title":"Sci Rep"},{"key":"421_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"421_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455\u201361.","journal-title":"J Comput Chem"},{"key":"421_CR18","first-page":"1670014","volume":"2022","author":"Z Luo","year":"2022","unstructured":"Luo Z, Xia LY, Tang YQ, Huang L, Liu D, Huai WY, Zhang CJ, Wang YQ, Xie YM, Yin QZ, Chen YH, Zhang TE. Action mechanism underlying improvement effect of Fuzi Lizhong Decoction on nonalcoholic fatty liver disease: A study based on network Pharmacology and molecular Docking. Evid Based Complement Alternat Med. 2022;2022:1670014.","journal-title":"Evid Based Complement Alternat Med"},{"key":"421_CR19","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.2147\/DDDT.S323360","volume":"15","author":"K Wang","year":"2021","unstructured":"Wang K, Miao X, Kong F, Huang S, Mo J, Jin C, Zheng Y. Integrating network Pharmacology and experimental verification to explore the mechanism of effect of Zuojin pills in pancreatic cancer treatment. Drug Des Devel Ther. 2021;15:3749\u201364.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"421_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40659-020-00316-0","volume":"53","author":"J Gao","year":"2020","unstructured":"Gao J, Chen F, Fang H, Mi J, Qi Q, Yang M. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice. Biol Res. 2020;53(1):48.","journal-title":"Biol Res"},{"issue":"9","key":"421_CR21","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.4049\/jimmunol.0902464","volume":"184","author":"K Guilloteau","year":"2010","unstructured":"Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, Guillet G, Bernard FX, Lecron JC, Morel F. Skin inflammation induced by the synergistic action of IL-17A, IL-22, Oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J Immunol. 2010;184(9):5263\u201370.","journal-title":"J Immunol"},{"key":"421_CR22","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2147\/CCID.S430621","volume":"16","author":"LL Yuan","year":"2023","unstructured":"Yuan LL, Cao CY, Rehmannioside. A inhibits TRAF6\/MAPK pathway and improves psoriasis by interfering with the interaction of HaCaT cells with IL-17A. Clin Cosmet Investig Dermatol. 2023;16:2585\u201396.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"421_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00403-018-1879-8","volume":"311","author":"M Zhang","year":"2019","unstructured":"Zhang M, Zhang X. The role of PI3K\/AKT\/FOXO signaling in psoriasis. Arch Dermatol Res. 2019;311(2):83\u201391.","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"421_CR24","doi-asserted-by":"publisher","first-page":"e027685","DOI":"10.1136\/bmjopen-2018-027685","volume":"9","author":"J Li","year":"2019","unstructured":"Li J, Yu M, Wang YW, Zhang JA, Ju M, Chen K, Jiang Y, Li M, Chen XS. Prevalence of psoriasis and associated risk factors in China: protocol of a nationwide, population-based, cross-sectional study. BMJ Open. 2019;9(7):e027685.","journal-title":"BMJ Open"},{"key":"421_CR25","doi-asserted-by":"publisher","first-page":"4683254","DOI":"10.1155\/2020\/4683254","volume":"2020","author":"L Zhou","year":"2020","unstructured":"Zhou L, Zhang L, Tao D. Investigation on the mechanism of Qubi formula in treating psoriasis based on network Pharmacology. Evid Based Complement Alternat Med. 2020;2020:4683254.","journal-title":"Evid Based Complement Alternat Med"},{"key":"421_CR26","doi-asserted-by":"publisher","first-page":"e927421","DOI":"10.12659\/MSM.927421","volume":"27","author":"S Guo","year":"2021","unstructured":"Guo S, Zhou JY, Tan C, Shi L, Shi Y, Shi J. Network Pharmacology-Based analysis on the mechanism of action of ephedrae Herba-Cinnamomi ramulus couplet medicines in the treatment for psoriasis. Med Sci Monit. 2021;27:e927421.","journal-title":"Med Sci Monit"},{"key":"421_CR27","doi-asserted-by":"crossref","unstructured":"But PP, Tam YK, Lung LC. Ethnopharmacology of rhinoceros Horn. II: antipyretic effects of prescriptions containing rhinoceros Horn or water Buffalo Horn. J Ethnopharmacol 1991 May-Jun;33(1\u20132):45\u201350.","DOI":"10.1016\/0378-8741(91)90159-B"},{"issue":"21","key":"421_CR28","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.12998\/wjcc.v10.i21.7224","volume":"10","author":"Z Wang","year":"2022","unstructured":"Wang Z, Zhang HM, Guo YR, Li LL. Molecular mechanisms of Biyu Decoction as treatment for psoriasis: A network Pharmacology and molecular Docking study. World J Clin Cases. 2022;10(21):7224\u201341.","journal-title":"World J Clin Cases"},{"key":"421_CR29","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.2147\/DDDT.S417954","volume":"17","author":"Y Guo","year":"2023","unstructured":"Guo Y, Gan H, Xu S, Zeng G, Xiao L, Ding Z, Zhu J, Xiong X, Fu Z. Deciphering the mechanism of Xijiao Dihuang Decoction in treating psoriasis by network Pharmacology and experimental validation. Drug Des Devel Ther. 2023;17:2805\u201319.","journal-title":"Drug Des Devel Ther"},{"key":"421_CR30","doi-asserted-by":"publisher","first-page":"606065","DOI":"10.3389\/fgene.2021.606065","volume":"12","author":"W Su","year":"2021","unstructured":"Su W, Wei Y, Huang B, Ji J. Identification of hub genes and immune infiltration in psoriasis by bioinformatics method. Front Genet. 2021;12:606065.","journal-title":"Front Genet"},{"key":"421_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.intimp.2017.04.022","volume":"48","author":"H Chen","year":"2017","unstructured":"Chen H, Lu C, Liu H, Wang M, Zhao H, Yan Y, Han L. Quercetin ameliorates imiquimod-induced psoriasis-like skin inflammation in mice via the NF-\u03baB pathway. Int Immunopharmacol. 2017;48:110\u20137.","journal-title":"Int Immunopharmacol"},{"key":"421_CR32","doi-asserted-by":"publisher","first-page":"110696","DOI":"10.1016\/j.biopha.2020.110696","volume":"131","author":"W Zhou","year":"2020","unstructured":"Zhou W, Hu M, Zang X, Liu Q, Du J, Hu J, Zhang L, Du Z, Xiang Z. Luteolin attenuates imiquimod-induced psoriasis-like skin lesions in BALB\/c mice via suppression of inflammation response. Biomed Pharmacother. 2020;131:110696.","journal-title":"Biomed Pharmacother"},{"key":"421_CR33","doi-asserted-by":"publisher","first-page":"109585","DOI":"10.1016\/j.intimp.2022.109585","volume":"114","author":"Y Li","year":"2023","unstructured":"Li Y, Cui H, Li S, Li X, Guo H, Nandakumar KS, Li Z. Kaempferol modulates IFN-\u03b3 induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions. Int Immunopharmacol. 2023;114:109585.","journal-title":"Int Immunopharmacol"},{"key":"421_CR34","doi-asserted-by":"publisher","first-page":"110202","DOI":"10.1016\/j.intimp.2023.110202","volume":"119","author":"ZY Chang","year":"2023","unstructured":"Chang ZY, Chen CW, Tsai MJ, Chen CC, Alshetaili A, Hsiao YT, Fang JY. The Elucidation of structure-activity and structure-permeation relationships for the cutaneous delivery of phytosterols to attenuate psoriasiform inflammation. Int Immunopharmacol. 2023;119:110202.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"421_CR35","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41419-021-04342-y","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang C, Zeng J, Li LJ, Xue M, He SL. Cdc25A inhibits autophagy-mediated ferroptosis by upregulating ErbB2 through PKM2 dephosphorylation in cervical cancer cells. Cell Death Dis. 2021;12(11):1055.","journal-title":"Cell Death Dis"},{"issue":"7","key":"421_CR36","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1042\/CS20191215","volume":"134","author":"D Di Fusco","year":"2020","unstructured":"Di Fusco D, Stolfi C, Di Grazia A, Dinallo V, Laudisi F, Marafini I, Colantoni A, Monteleone I, Monteleone G. Albendazole negatively regulates keratinocyte proliferation. Clin Sci (Lond). 2020;134(7):907\u201320.","journal-title":"Clin Sci (Lond)"},{"key":"421_CR37","doi-asserted-by":"publisher","first-page":"918959","DOI":"10.3389\/fonc.2022.918959","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Yang H, Wang L, Zhou H, Zhang G, Xiao Z, Xue X. TOP2A correlates with poor prognosis and affects radioresistance of Medulloblastoma. Front Oncol. 2022;12:918959.","journal-title":"Front Oncol"},{"key":"421_CR38","doi-asserted-by":"crossref","unstructured":"Zhu X, Zhang E, Qin L. The high expression of TOP2A and MELK induces the occurrence of psoriasis. Aging. 2024;16.","DOI":"10.18632\/aging.205519"},{"issue":"8","key":"421_CR39","doi-asserted-by":"publisher","first-page":"119525","DOI":"10.1016\/j.bbamcr.2023.119525","volume":"1870","author":"Y Peng","year":"2023","unstructured":"Peng Y, Zhang Y, Luo M, Pan Y, Zhou R, Yan YN, Yi T, Luo F, Wang B, Wang L, Ran C, Wang H. NEK2 overexpression aggravates IL-22-induced keratinocyte proliferation and cytokine level increases and IMQ-induced psoriasis-like dermatitis. Biochim Biophys Acta Mol Cell Res. 2023;1870(8):119525.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"11","key":"421_CR40","doi-asserted-by":"publisher","first-page":"e80751","DOI":"10.1371\/journal.pone.0080751","volume":"8","author":"M Manczinger","year":"2013","unstructured":"Manczinger M, Kem\u00e9ny L. Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach. PLoS ONE. 2013;8(11):e80751.","journal-title":"PLoS ONE"},{"issue":"1","key":"421_CR41","doi-asserted-by":"publisher","first-page":"8590","DOI":"10.1038\/s41598-018-26996-z","volume":"8","author":"C Chen","year":"2018","unstructured":"Chen C, Wu N, Duan Q, Yang H, Wang X, Yang P, Zhang M, Liu J, Liu Z, Shao Y, Zheng Y. C10orf99 contributes to the development of psoriasis by promoting the proliferation of keratinocytes. Sci Rep. 2018;8(1):8590.","journal-title":"Sci Rep"},{"issue":"7","key":"421_CR42","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s11010-022-04599-7","volume":"478","author":"R Aldabbas","year":"2023","unstructured":"Aldabbas R, Shaker OG, Ismail MF, Fathy N. miRNA-559 and MTDH as possible diagnostic markers of psoriasis: role of PTEN\/AKT\/FOXO pathway in disease pathogenesis. Mol Cell Biochem. 2023;478(7):1427\u201338.","journal-title":"Mol Cell Biochem"},{"issue":"36","key":"421_CR43","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1038\/onc.2009.171","volume":"28","author":"J Li","year":"2009","unstructured":"Li J, Yang L, Song L, Xiong H, Wang L, Yan X, Yuan J, Wu J, Li M. Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1. Oncogene. 2009;28(36):3188\u201396.","journal-title":"Oncogene"},{"key":"421_CR44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579.","journal-title":"Front Immunol"},{"key":"421_CR45","doi-asserted-by":"publisher","first-page":"925503","DOI":"10.3389\/fimmu.2022.925503","volume":"13","author":"A Saalbach","year":"2022","unstructured":"Saalbach A, Kunz M. Impact of chronic inflammation in psoriasis on bone metabolism. Front Immunol. 2022;13:925503.","journal-title":"Front Immunol"},{"key":"421_CR46","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Parra S, Daud\u00e9n E. Psoriasis and depression: the role of inflammation. Actas Dermosifiliogr (Engl Ed). 2019 Jan-Feb;110(1):12\u20139.","DOI":"10.1016\/j.adengl.2018.05.035"},{"issue":"5","key":"421_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/exd.12128","volume":"22","author":"RM Andr\u00e9s","year":"2013","unstructured":"Andr\u00e9s RM, Hald A, Johansen C, Kragballe K, Iversen L. Studies of Jak\/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Exp Dermatol. 2013;22(5):323\u20138.","journal-title":"Exp Dermatol"},{"key":"421_CR48","doi-asserted-by":"publisher","first-page":"105452","DOI":"10.1016\/j.ebiom.2024.105452","volume":"110","author":"AR Liu","year":"2024","unstructured":"Liu AR, Sarkar N, Cress JD, de Jesus TJ, Vadlakonda A, Centore JT, Griffith AD, Rohr B, McCormick TS, Cooper KD, Ramakrishnan P. NF-\u03baB c-Rel is a critical regulator of TLR7-induced inflammation in psoriasis. EBioMedicine. 2024;110:105452.","journal-title":"EBioMedicine"},{"issue":"2","key":"421_CR49","doi-asserted-by":"publisher","first-page":"e70054","DOI":"10.1111\/exd.70054","volume":"34","author":"JC Freisenhausen","year":"2025","unstructured":"Freisenhausen JC, Luo L, Kelemen E, Elton J, Skoog V, Pivarcsi A, Sonkoly E. RNA sequencing reveals the long Non-Coding RNA signature in psoriasis keratinocytes and identifies CYDAER as a long Non-Coding RNA regulating epidermal differentiation. Exp Dermatol. 2025;34(2):e70054.","journal-title":"Exp Dermatol"},{"issue":"10","key":"421_CR50","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.3390\/ijms24108502","volume":"24","author":"M Di Vincenzo","year":"2023","unstructured":"Di Vincenzo M, Diotallevi F, Piccirillo S, Carnevale G, Offidani A, Campanati A, Orciani M, miRNAs. Mesenchymal stromal cells and major neoplastic and inflammatory skin diseases: A page being written: A systematic review. Int J Mol Sci. 2023;24(10):8502.","journal-title":"Int J Mol Sci"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00421-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00421-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00421-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:39:12Z","timestamp":1744202352000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00421-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00421-8","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}